Genomic Solution * Hurra, wir leben noch !!! - 500 Beiträge pro Seite

[Mattek]

hoffe, es sind noch ein paar gnsl-investierte vorhanden. nach einem mächtigen sturz von 60 % innerhalb von vier Wochen, startet gerade die auferstehung in usa (+15,5 %)

-RSI bei < 35
-fast Stochastik hat gedreht
-Meldungen über gesetzliche weiterungen in der genom-forschung in england
- sehr gute q2-pays
- break-even-point ende 2001 erwartet

wer hat weitere infos (positv/negativ)?

gruss und allen gute geschäfte
mattek

[Mattek]

doch dann: 20,10 % am schluss

habe keine grosse lust, gnsl nochmals vorzustellen. einfach in die boardbeiträge schauen.

gute geschäfte wünscht euch
mattek

[Mattek]

@gnsl-Jünger,

meine damalige Überschrift passt heute mal wieder:

Genomic Solutions Expects Record First Quarter Sales
ANN ARBOR, Mich., April 8 /PRNewswire-FirstCall/ -- Genomic Solutions Inc. (Nasdaq: GNSL - news), a leading global supplier of automated life science research solutions for genomics, proteomics, and high throughput screening, announced today strong first quarter sales to all customer market segments including academia, pharmaceutical, and biotech.

Jeffrey S. Williams, President and CEO of Genomic Solutions commented, ``During the first quarter of 2002, we completed the sale of more than 75 large units, defined as the sale of a unit priced at $25,000 or more. We are especially pleased with customer demand for our newest products, including strong demand for the Investigator(TM) ProPrep Proteomic Workstation, GeneTAC(TM) UC4 Microarray Scanner and Cartesian(TM) Hummingbird liquid handlers. In addition, we completed several installations of proteomic software obtained through our exclusive licensing arrangement with ProteoMetrics, LLC, including our first Investigator PWRHouse(TM) proteomic data management system installation.``

The company reports its installed base now totals over 715 large units as compared to the 640 (excluding Cartesian Technologies installed base) installed as of fourth quarter, 2001. In addition, the Company announced that it expects revenue for the first quarter to exceed $6.6 million, although this is a preliminary financial estimate that is subject to final accounting and review processes.

``Our product acceptance is strong and our recent strategic changes in marketing, sales and distribution optimize our ability to sell and support these products,`` stated Mr. Williams. ``In addition, we have significantly strengthened our product offering through the acquisition of Cartesian Technologies and the recently announced exclusive licensing arrangement with ProteoMetrics, LLC. These transactions have allowed us to expand our product base of drug discovery tools into high throughput screening and have also enhanced our bioinformatics portfolio with software that creates synergy`s across our entire proteomic product portfolio. Combined with the results of last year`s restructuring and cost reduction initiatives, we continue to make significant strides toward profitability and implementation of our business plan.``

``Our primary operating goal for 2002 remains unchanged. The Company is focused on achieving profitability and generating positive EBITDA during 2002. We are confident we will continue to grow by providing innovative solutions with our wide-ranging portfolio of quality instruments, consumables and software,`` Mr. Williams concluded.

About Genomic Solutions Inc.

The company develops, manufactures, and sells instruments, software, and consumables used by life science researchers to determine the activity level of genes, to isolate, identify and characterize proteins, and to dispense small volumes of biologically important materials. The company`s products and systems, marketed under the GeneTAC(TM) Biochip System, Investigator(TM) Proteomic System, Cartesian(TM) nanoliter dispensing systems, and GeneMAP(TM) preprinted arrays` brands, enable researchers to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. As a result, Genomic Solutions products and systems facilitate more rapid and less expensive drug discovery.

Special Note

This press release contains ``forward-looking`` statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as ``believes,`` ``forecasts,`` ``anticipates,`` ``plans,`` ``expects,`` ``will`` and similar expressions are intended to identify forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: a downturn in our customers` markets or in general economic conditions; our failure to introduce new products in a timely manner; economic, political and other risks associated with international sales and operations; difficulties integrating technologies, operations and personnel of recent acquisitions; competition from third parties, including pricing pressure; governmental regulation; research and development progress, and our level of debt and the possible incurrence of additional debt in the future. These and other important factors that may affect our actual results are more fully described under ``Risk Factors`` in Genomic Solutions` Form 10-K for the year ended December 31, 2001 and in Genomic Solutions other filings with the Securities and Exchange Commission, including the Company`s most recent quarterly report on Form 10-Q and the Form S-4 filing in connection with the Company`s acquisition of Cartesian Technologies, Inc.

For more information, contact Genomic Solutions at [e-mail] or visit the company`s Web site, at http://www.genomicsolutions.com .

SOURCE: Genomic Solutions Inc.


Email this story - Most-emailed articles - Most-viewed articles


--------------------------------------------------------------------------------
More Quotes and News: Genomic Solutions Inc (NasdaqNM:GNSL - news)